A cost-effectiveness analysis of pretreatment DPYD and UGT1A1 screening in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI+bevacizumab (FOLFIRI+Bev).

Zachary Rivers,David D. Stenehjem,Pamala A. Jacobson,Emil Lou,Andrew C. Nelson,Karen M. Kuntz

A cost-effectiveness analysis of pretreatment DPYD and UGT1A1 screening in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI+bevacizumab (FOLFIRI+Bev).

2020

Zachary Rivers
David D. Stenehjem
Pamala A. Jacobson
Emil Lou
Andrew C. Nelson
Karen M. Kuntz

168Background: Variants in DPYD and UGT1A1 impact toxicities experienced by patients being treated with FOLFIRI+bev. Testing allows providers to preemptively adjust dosing, reducing the toxicity th...

Keywords:

FOLFIRI
Internal medicine
Colorectal cancer
Bevacizumab
DPYD
Medicine
Oncology
Cost-effectiveness analysis
Pathology
Toxicity
in patient
Dosing
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations